Safety, Toleration and Efficacy of Single Inhaled Doses of PF-00610355 in Chronic Obstructive Pulmonary (COPD) Patients.

A Phase 2A, Double Blind (3rd Party Open), 4 Way Cross-Over, Placebo Controlled Study To Investigate The Pharmacokinetics, Safety, Toleration And Efficacy Of Single Inhaled Doses Of PF-00610355 In Moderate COPD Patients.

This study will look at the pharmacokinetics, safety, toleration and efficacy of PF-00610355 in the chronic obstructive pulmonary disease (COPD) population. The doses in this study are intended to explore the anticipated clinical dose range.

Inclusion Criteria:

• Post-bronchodilator FEV1/ FVC ratio of <0.7.
• Post bronchodilator FEV1 of 50-80% (inclusive) of predicted.
• Body Mass Index (BMI) of less than 35 kg/m2; and a total body weight greater that 40 kg.
• Current smokers, or ex-smokers who have abstained from smoking for at least 6 months.

Exclusion Criteria:

• Subjects having more than 2 exacerbations requiring treatment with oral steroids or hospitalization for the treatment of COPD in the previous year.
• History of lower respiratory tract infection or significant disease instability during the month preceding screening or during the period between screening and randomization.